| Size | Price | Stock |
|---|---|---|
| 2mg | $50 | In-stock |
| 5mg | $85 | In-stock |
| 10mg | $135 | In-stock |
| 50mg | $450 | In-stock |
| 100mg | $720 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-B1831A |
| M.Wt: | 1989.09 |
| Formula: | C86H103Cl3N10O34P2 |
| Purity: | >98 % |
| Solubility: | DMSO : 41.67 mg/mL (ultrasonic);H2O : 50 mg/mL (ultrasonic) |
Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity[1][2][3][4][5].
In Vitro: Oritavancin diphosphate (25 μM, 30 min) dose-dependently inhibits the kinase activity of ArlS (3 μg) by 98% with an IC50 value of 5.47 μΜ in vitro[1].
Oritavancin diphosphate (0.7 μM, 42 h) decreases spx expression in the USA300-Pspx strain[1].
Oritavancin diphosphate (3.1 μM, 24 h) disrupts mature MRSA biofilms and facilitates bactericidal activity of oritavancin diphosphate and Oxacillin (HY-B0925A) against embedded S. aureus cells[1].
Oritavancin diphosphate’ (0-80 μg/mL, 2 h) incubation with increasing extracellular concentrations and the uptake by cells proceed in a cooperative manner in J774 macrophages[2].
Oritavancin diphosphate (25 mg/L, 24 h) exerts a marked bactericidal effect against intracellular S. aureus[2].
Oritavancin diphosphate accumulation by different cell types[2]
(The cells were incubated for 2 h at 37°C with 25 mg of the drug per liter in a medium containing 10% FCS)[2]
| Cell type | Accumulation ratio (no. of determinations) |
| J774 mouse macrophages | 66.4±11.8 (12) |
| THP-1 human monocytes | 84.3±7.0 (9) |
| Rat embryo fibroblasts | 72.4±9.4 (6) |
| LLC-PK1 pig kidney proximal tubular cells | 37.8±6.4 (3) |
| Caco-2 human colorectal cells. | 13.8±0.4 (3) |